iFIND TBR MTB/RIF Cartridge: Evidence and Procurement Guide
Evidence-based procurement guide for the iFIND TBR MTB/RIF cartridge: peer-reviewed data, brochure claims, regulatory gaps, and 12-point checklist.
Research archive
China & Global Biomed
Source-backed biomed industry news, regulation, clinical development, medtech, import/export platforms, and market signals. Not medical advice.
海关总署令281号详解：2026年特殊物品进出境合规自查清单
面向CRO、IVD、细胞与基因治疗及跨境物流团队，详解海关总署令第281号中特殊货物物品范围、审批材料时限、查验与记录要求，附可打印自查清单与新旧流程对比。
Fully Automated Molecular POCT: iFIND S2/S4/S8 Procurement Guide
A procurement guide for fully automated molecular POCT systems: what evidence to request before shortlisting a cartridge-based PCR analyzer like RocGene iFIND.
深圳生物医药特殊物品进出口机制：哪些环节真的变快了？
深度解析深圳出入境生物医药特殊物品联合监管机制：白名单与正面清单制度、GACC 2025年第65号公告对D类物品的监管调整、迈瑞医疗首单案例、坪山综合服务平台建设，以及2026年”出口深圳”十条中”非药用用途免进口药品通关单”政策。覆盖适用范围、新旧流程对比、监管部门、所需文件、排除范围、操作瓶颈与企业自查清单。
Bristol Myers’ AI Factory and Samsung’s Peptide Bet: Two Pharma Signals
Bristol Myers’ Nvidia AI factory and Samsung Biologics’ PolyPeptide bid point to two biopharma priorities: data-driven R&D and peptide manufacturing capacity.
Tempus to Buy Personalis for $1.5B: What the MRD Deal Signals
Tempus AI agreed to acquire Personalis for $1.5B, adding tumor-informed MRD tests. We analyze what this means for the cancer diagnostics market and competitive landscape.